Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eupraxia Pharmaceuticals Inc. (EPRX : NSDQ)

• Company Description    Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $5.45 Daily Weekly Monthly 20 Day Moving Average: 90,515 shares Shares Outstanding: 35.96 (millions) Market Capitalization: $195.99 (millions) Beta: 1.47 52 Week High: $7.19 52 Week Low: $2.68 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.21% -12.57% 12 Week 2.38% -1.86% Year To Date 71.92% 50.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201-2067 CADBORO BAY RD. - VICTORIA,A1 V8R5G4 CAN ph: 250-590-3968 fax: - investors@eupraxiapharma.com http://www.eupraxiapharma.com/home/default.aspx

• General Corporate Information    Officers James A. Helliwell - Chief Executive Officer Simon Pimstone - Chairman Alex Rothwell - Chief Financial Officer and President Richard M. Glickman - Director John Montalbano - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29842P105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 35.96 Most Recent Split Date: (:1) Beta: 1.47 Market Capitalization: $195.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.45 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -11.76% vs. Previous Quarter: 26.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -283.52 06/30/25 - - 03/31/25 - -626.84 ROA 09/30/25 - -65.28 06/30/25 - -118.31 03/31/25 - -105.68 Current Ratio 09/30/25 - 23.98 06/30/25 - 8.72 03/31/25 - 13.00 Quick Ratio 09/30/25 - 23.98 06/30/25 - 8.72 03/31/25 - 13.00 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 1.58 06/30/25 - -0.30 03/31/25 - -0.13 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - 0.11 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©